

Published online: 21 January 2020

## **OPEN Author Correction: Dysfunctional EAT thickness may promote** maladaptive heart remodeling in CVD patients through the ST2-IL33 system, directly related to EPAC protein expression


Elena Vianello, Elena Dozio, Francesco Bandera, Gerd Schmitz, Manuela Nebuloni, Erika Longhi, Lorenza Tacchini, Marco Guazzi & Massimiliano Marco Corsi Romanelli

Correction to: Scientific Reports https://doi.org/10.1038/s41598-019-46676-w, published online 17 July 2019


This Article contains errors. In Figure 1a, the incorrect image was used for panel a3, and the labelling of these panels was inconsistent. The correct Figure and Legend appears below, in Fig. 1.

The scale bars provided in Figure 2c are incorrect. The correct Figure 2c appears below as Fig. 2, with information on magnification provided in the legend.

The Supplementary Information did not include full-length gel images. Uncropped images for gels used in Figure 2b and 3b are provided below as Fig. 3.



**Figure 1.** EAT thickness directly correlates with ST2 expression and inversely with IL-33. (**A**) Echocardiographic frames showing EAT thickness (red arrows): a1, long axis end-diastolic frame; a2, short axis end-diastolic frame; a3, long axis end-systolic frame; a4, zoom of long axis view of end-systolic. (**B**) Correlation results among EAT measurement and both ST2 molecular expression (r = 0.54, p < 0.0001) and IL-33 (Spearmann r = -0.50; p < 0.01) suggesting a potential involvement of fat body increase in ST2/IL-33 regulation.



**Figure 2.** Representative images of EAT biopsies with immunoreaction for ST2 and IL-33 positive cells in separate panels (panel **I** at 10X and panel **II** at 20X of magnification respectively). Both ST2 immunoreactivity and IL-33 are present in EAT biopsies specially those close to endothelial vessels.

## Panel a Panel b Panel c Panel c Panel c Panel c Panel c

**Figure 3.** (**Panel a**) shows the full gel provided in Figure 3a of the Article as EPAC1; (**Panel b**) shows the stainfree gel shown in Figures 2b and 3a of the Article, and used as normalizer for ST2 and EPAC1 immunoblots after stripping phase; (**Panel c**) shows the full membrane provided in Figure 2b of the Article as ST2; (**Panel d**) shows the full membrane provided in Figure 3a of the Article as EPAC2; (**Panel e**) shows the gel for a stain free gel shown in membrane provided in Figures and 2b and 3a of the Article, and used as normalizer for IL-33 and EPAC2 immunoblots after stripping phase; (**Panel f**) shows the full gel provided in Figure 2b of the Article as IL-33.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>.

© The Author(s) 2020